Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > He says so many things to himself, but what's the truth!

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Aug 26, 2020 9:35pm

157 Views

Post# 31458560

RE:He says so many things to himself, but what's the truth!

Lmao, it's a repurposed drug, they still don't have a patent and other companies are running trials around the world with it aswell. They want to make a inhaler and patent its use.... anyways good luck but don't bet the farm.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023